(Q41504176)

1 October 2017

title

Impact of disease location on fecal calprotectin levels in Crohn's disease (English)

1 reference

1 October 2017

1 reference

7

Geert D'Haens

1 reference

1 October 2017

Krisztina B Gecse

1

1 reference

1 October 2017

Johannan F Brandse

2

1 reference

1 October 2017

Sandra van Wilpe

3

1 reference

1 October 2017

Mark Löwenberg

4

1 reference

1 October 2017

Cyriel Ponsioen

5

1 reference

1 October 2017

Gijs van den Brink

6

1 reference

1 October 2017

publication date

30 January 2015

1 reference

Scandinavian Journal of Gastroenterology

1 October 2017

published in

1 reference

1 October 2017

volume

50

1 reference

1 October 2017

issue

7

1 reference

1 October 2017

page(s)

841-847

1 reference

Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

1 October 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2015.1008035

Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2015.1008035

Laboratory markers in IBD: useful, magic, or unnecessary toys?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2015.1008035

A simple method for assessing intestinal inflammation in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2015.1008035

Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2015.1008035

Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2015.1008035

Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2015.1008035

Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2015.1008035

Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2015.1008035

Faecal calprotectin but not C-reactive protein (CRP) or Crohn's Disease Activity Index (CDAI) may predict post-operative endoscopic recurrence of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2015.1008035

Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2015.1008035

A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2015.1008035

Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2015.1008035

Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2015.1008035

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2015.1008035

10.3109/00365521.2015.1008035

21 January 2018

Identifiers

DOI

1 reference

1 October 2017

1 reference